AZD 2066 is a selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme that breaks down endocannabinoids. It is primarily investigated for therapeutic applications in medicine, particularly for chronic pain conditions such as osteoarthritis and neuropathic pain, as well as post-traumatic stress disorder (PTSD). By inhibiting FAAH, AZD 2066 elevates endocannabinoid levels, which modulate pain, inflammation, mood, and anxiety. This positions it as a promising option where conventional treatments fall short. Clinical trials have evaluated its efficacy and safety, underscoring interest in the endocannabinoid system for therapy.